TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05430386
Drug: HS-10241
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation: HS-10241 and Almonertinib will be administered in combination. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.~Dose expansion: HS-10241 and Almonertinib will be administered in the dose identified in Part 1 to further investigate the safety, tolerability, pharmacokinetics, and efficacy of this combination therapy.
Study: NCT05485987
Drug: Vatiquinone
Normalized name: Vatiquinone
DrugBank: Vatiquinone (DB11917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vatiquinone will be administered per dose and schedule specified in the arm.
Study: NCT06139952
Drug: Atorvastatin 80mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 80MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 80mg taken Once before coronary angiography
Study: NCT06139952
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg 3 times daily 2 days before coronary angiography
Study: NCT04383275
Drug: capecitabine and trastuzumab
Normalized name: Capecitabine
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In IRIS-A cohort, patients who met the inclusion criteria(ER，PR\<10%, T≤2cm or ER,PR ≥10% 1cm\<T≤2cm）would be given capecitabine for 6 cycles with standard trastuzumab for 1 year, in which HR+ patients would be given endocrine therapy for 5 years.
Study: NCT04383275
Drug: endocrine therapy and trastuzumab
Normalized name: ENDOCRINE THERAPY
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In IRIS-B cohort, patients who met the inclusion criteria(ER,PR ≥10% T≤1cm) would be given endocrine therapy (premenopausal: tamoxifen or toremifene; postmenopausal: letrozole or anastrozole or exemestane) combined with standard trastuzumab for 1 year and complete endocrine therapy for 5 years.
Study: NCT05927233
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 ml Methylprednisolone (30mg/kg) with a maximum dose of 500 mg
Study: NCT05927233
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 ml Normal saline
Study: NCT05493995
Drug: Penpulimab
Normalized name: Penpulimab
DrugBank: Penpulimab (DB16747)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penpulimab 200 mg administered intravenously every 3 weeks.
Study: NCT05493995
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.
Study: NCT05493995
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 125mg/m\^2，administered intravenously on days 1 and 8 of every 21-day cycle.
Study: NCT05493995
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.0g/m\^2, administered intravenously on days 1 and 8 of every 21-day cycle.
Study: NCT04862091
Drug: Abiraterone Acetate Tablets (I)
Normalized name: Abiraterone Acetate
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone Acetate Tablets (I)
Study: NCT05597020
Drug: Daridorexant
Normalized name: Daridorexant
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daridorexant is available as oral film-coated tablets at a strength of 50 mg.
Study: NCT06347354
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subdermal injection of 2,5 mg (1 cc) of ICG
Study: NCT06573164
Drug: Bacillus clausii tablets（Qipian®）
DrugBank: Bacillus clausii (DB16537)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take 4 tablets (0.3 mg each) orally three times daily.
Study: NCT06574347
Drug: Vebreltinib
Normalized name: Vebreltinib
DrugBank: Vebreltinib (DB16823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive Vebreltinib orally twice per day (BID).
Study: NCT06574347
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will receive Osimertinib 80mg orally once per day (QD).
Study: NCT05314153
Drug: Brexanolone
Normalized name: Brexanolone
DrugBank: Brexanolone (DB11859)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brexanolone injection is an Federal Drug Administration (FDA)-approved drug to treat postpartum depression. It is administered via continuous intravenous infusion over a 60-hour time period.
Study: NCT06663787
Drug: Trastuzumab (Herceptin)
Normalized name: trastuzumab Injection [Herceptin]
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Continuing anti-HER2 treatment
Study: NCT05060419
Drug: Meropenem- FL058
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem-FL058(Meropenem 1000mg plus FL058 1000mg)q8h~Meropenem-FL058(Meropenem 2000mg plus FL058 1000mg)q8h
Study: NCT05060419
Drug: Piperacillin -tazobactam
Normalized name: piperacillin / tazobactam
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piperacillin-tazobactam (piperacillin 4 g plus tazobactam 0.5 g)q8h
Study: NCT05060419
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 180min
Study: NCT05060419
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30min
Study: NCT03759093
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
Study: NCT03759093
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
Study: NCT03759093
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
Study: NCT03759093
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose in a range of 0.7,1.0,1.3 mg/m2 subcutaneous (SC) injection on Day 1, 8, 15 ,22 for cycles 1 to 4 , as determined and guided by CURATE.AI and approved by the clinical care team
Study: NCT03759093
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose in a range of 50-200mg PO on day 1-28 for cycles 1 to 4 as determined and guided by CURATE.AI and approved by the clinical care team.
Study: NCT03759093
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg PO on Day 1 ,8 , 15, 22 for cycles 1 to 4, as determined and guided by the clinical care team according to standard of care
Study: NCT03759093
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
Study: NCT03759093
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose in a range of 5-25mg PO on day 1-21 for cycles 1 to 4, as determined and guided by CURATE.AI and approved by the clinical care team.
Study: NCT00253526
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00253526
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05951816
Drug: 99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m.
DrugBank: Amyl acetate (DB15927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide p5+14 is a pan-amyloid reactive, synthetic 45 L-amino acid polypeptide with a net +12 positive charge that can bind two major components of all extracellular amyloid deposits: (i) hypersulfated heparan sulfate glycosaminoglycans (proteoglycans) and (ii) amyloid fibrils. The polypeptide, labeled with iodine-124, has been shown (study AMY1001) to bind amyloid in all organs including the heart. This study will evaluate a Tc-99m-labeled version of the peptide for gamma imaging.
Study: NCT05951816
Drug: 99mTc-Pyrophosphate and 99mtc-p5+14 - an Amyloid Reactive Peptide Labeled With Technetium-99m.
DrugBank: Amyl acetate (DB15927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc-PYP is an FDA-approved, commercially available bone-seeking radiotracer used routinely in nuclear medicine. 99mTC-PYP imaging is used clinically for the diagnosis of cardiac ATTR amyloidosis.
Study: NCT06442267
Drug: Enoxaparin Injectable Solution
Normalized name: enoxaparin Injectable Solution
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Enoxaparin will be dosed at 0.5 mg/kg twice daily
Study: NCT06442267
Drug: Argatroban, 1 Mg/mL Intravenous Solution
Normalized name: Argatroban, 1 mg/mL intravenous solution
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Argatroban will be administered as a continuous infusion of 0.1-1 µg/kg/min with a target modified thrombin time measured using Hemoclot of 0,40 - 0,60 µg/mL.
Study: NCT06442267
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin will be administered as a continuous infusion of 7.5-20 units/kg/h with a target Anti FXa calibrated for UFH of 0.3-0.5 u/mL.
Study: NCT06271551
Drug: Transdermal estrogen
Normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants (n=155) receiving transdermal estradiol for 12 months.
Study: NCT05660616
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The study includes patients with unresectable malignant pleural mesothelioma who received at least 4 cycles of first line platinum (Cisplatin or Carboplatin) and pemetrexed combination chemotherapy~* Response after first line treatment will be assessed by the modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1 for pleural mesothelioma.~* Patients will be randomized according to a (1:1) ratio to either Arm 1: Administration of maintenance gemcitabine (1000 mg/m²) on days 1 and day 8, in cycles of 21 days plus supportive care Arm 2 (control arm): best supportive care alone.~* Cases will be evaluated every cycle clinically and every three cycles radiologically with CTs.
Study: NCT05349448
Drug: Hylase plus Triamcinolone plus sterile isotonic saline
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: transforaminal fluroscopic epidural injection
Study: NCT05349448
Drug: Hylase plus Dexmedetomidine plus Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: transforaminal fluroscopic epidural injection
Study: NCT05833984
Drug: IMM01
Normalized name: IMM01
DrugBank: Timdarpacept (DB17544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMM01 (1.0, 1.5, 2.0 mg/kg) QW IV in the dose escalation part. IMM01 (dose determined in the dose escalation part) QW IV in the dose expansion part.
Study: NCT05833984
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab 200mg Q3W IV
Study: NCT04746937
Drug: Nitazoxanide
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nitazoxanide adjuvant to standard therapy
Study: NCT04746937
Drug: Norfloxacin
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard therapy
Study: NCT06034821
Drug: Subanesthetic dose intravenous ketamine (KET)
Normalized name: Mal-A-Ket
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This trial will use standard dose of ketamine (0.5mg/kg infusion over 40 min period) in accordance with research studies that have used ketamine as an antidepressant. Treatments will be given two times a week for a maximum of 8 treatments during the acute arm of the study. The investigators will be able to modify dose and number of treatments as indicated clinically per pragmatic clinical trials procedures. Patients will be clinically assessed prior to each treatment to evaluate response and appropriateness of continuation of treatment. Per FDA guidelines a maximum 60mg/dose will be given regardless of body weight.
Study: NCT05809895
Drug: Ociperlimab
Normalized name: Ociperlimab
DrugBank: Ociperlimab (DB18947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg intravenously (IV) every 3 weeks (Q3W)
Study: NCT05809895
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg intravenously (IV) Q3W
Study: NCT05809895
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 90 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days
Study: NCT05809895
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days
Study: NCT05809895
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 2 intravenously (IV) on Days 1 and 8 every 21 days
Study: NCT05809895
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg intravenously (IV) Q3W
Study: NCT05809895
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 intravenously (IV) on Days 1 and 8 every 21 days
Study: NCT02556008
Drug: cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment will begin with 2 mg/kg/day given in two divided doses. The dose will be increased by 3 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 25 mg/kg/day given.
Study: NCT06314698
Drug: Narlumosbart
Normalized name: Narlumosbart
DrugBank: Narlumosbart (DB19002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection once every 4 weeks.
Study: NCT06314698
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered by subcutaneous injection once every 4 weeks.
Study: NCT06572085
Drug: Butylphthalide and Sodium Chloride Injection
Normalized name: Butylphthalide
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the experimental group will receive intravenous infusion of 100ml NBP injection twice daily, while patients in the control group will receive intravenous infusion of 100ml saline solution twice daily. Each patient will receive continuous medication for 14 days.
Study: NCT06572085
Drug: Saline Solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the experimental group will receive intravenous infusion of 100ml NBP injection twice daily, while patients in the control group will receive intravenous infusion of 100ml saline solution twice daily. Each patient will receive continuous medication for 14 days.
Study: NCT05932316
Drug: Salbutamol
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol inhalation to determine bronchodilator response
Study: NCT05459129
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
Study: NCT05459129
Drug: Tiragolumab
Normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiragolumab will be administered intravenously at a fixed dose of 600 mg on Day 1 of each 21-day cycle.
Study: NCT05459129
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be administered intravenously at a dose of area under the concentration-time curve (AUC) 5 mg/mL/min on Day 1 of each 21 day cycle.
Study: NCT05459129
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel will be administered intravenously at a dose of 175 mg/m2 on Day 1 of each 21 day cycle.
Study: NCT05166967
Drug: Individual Antithymocyte globulin
Normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on pharmacokinetic index, within a range of 6 mg/kg to 13mg/kg). Prophylaxis against graft versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate.
Study: NCT05166967
Drug: Antithymocyte globulin
Normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 10mg/kg total dose of antithymocyte globulin (ATG) was added to conditioning regimens for 4 days (from day -5 to day -2). Prophylaxis against graft versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate.
Study: NCT05898087
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in this arm will receive an injection of 20cc of injectable saline. It will be injected in a fan-like pattern beneath the pectoralis fascia
Study: NCT05898399
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib will be given orally.
Study: NCT05898399
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Niraparib will be given orally.
Study: NCT05074433
Drug: casirivimab+imdevimab
Normalized name: casirivimab / imdevimab
DrugBank: Imdevimab (DB15940)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Co-administered sequentially subcutaneous (SC)
Study: NCT06041477
Drug: Concurrent Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib 8mg/day combined with the HAIC from the first cycle
Study: NCT06041477
Drug: Concurrent PD-1 antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 antibody which is approved by authorities for HCC treatment combined with the HAIC from the first cycle (dosage and frequency according to instructions)
Study: NCT06041477
Drug: Sequential Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib 8mg/day combined with the HAIC from the third cycle for those patients who do not achieve complete response (CR)
Study: NCT06041477
Drug: Sequential PD-1 antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 antibody which is approved by authorities for HCC treatment combined with the HAIC from the third cycle for those patients who do not achieve complete response (CR) (dosage and frequency according to instructions)
Study: NCT05085340
Drug: Intermittent preventive treatment of malaria in infants (IPTi) with sulfadoxine-pyrimethamine (SP)
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IPTi will be administered as full therapeutic courses of SP alongside routine EPI immunisations at defined intervals corresponding to vaccination schedules - usually at 10 weeks, 14 weeks, and 9 months of age - to infants living in project districts. Additional doses of IPTi will be administered at 6, 12, and 15 or 18 months of age, coinciding with vitamin A administration and measles booster immunisation. The number of doses of IPTi a child will receive will depend of the EPI schedule in the country, with a maximum of six doses in the first two years of life.
Study: NCT06467318
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants post mechanical pleurodesis on pneumothorax will be divided into two groups: Group A: patients taking classic pain management with NSAID. Group B: patients taking classic pain management without NSAID.
Study: NCT05676242
Drug: Jaktinib Hydrochloride Tablet
Normalized name: sevelamer hydrochloride Oral Tablet
DrugBank: Jaktinib (DB17545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered, twice a day
Study: NCT03676049
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CBD will be administered as an adjunct to all current antiepileptic drugs. A dosing titration period will start with 100 mg/day, with 50mg BID dosing, and will be titrated monthly as tolerated based on clinical response, up to 300mg/day. This is based on a targeted dosing of 2.5 ---5---7.5 mg/kg/d.
Study: NCT04875806
Drug: NC762
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: NC762 is an experimental antibody drug that may make the immune response more active against cancer
Study: NCT06081166
Drug: Obicetrapib
Normalized name: Obicetrapib
DrugBank: Obicetrapib (DB14890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: obicetrapib 10 mg daily
Study: NCT06081166
Drug: Atorvastatin Calcium
Normalized name: Atorvastatin Calcium
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 80 mg
Study: NCT01070290
Drug: ARQ 197
Normalized name: ARQ 092
DrugBank: Miransertib (DB14982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg capsule administered twice daily